Acute coronary syndromes

ESC 2025 | BETAMI-DANBLOCK: Randomized Discontinuation of Beta-Blockers after MI

The routine use of beta-blockers after acute myocardial infarction (AMI) has been a historical recommendation based on...

Dr. Omar Tupayachi - 4 September, 2025

Acute coronary syndromes

ESC 2025 | What Should We Do With Beta-Blockers Post-MI in Patients With Preserved LVEF?

The evidence supporting the use of beta-blockers after myocardial infarction (MI) is strong in patients with ventricular...

Dr. Juan Manuel Pérez - 3 September, 2025

Acute coronary syndromes

ESC 2025 | DUAL-ACS: Duration of Dual Antiplatelet Therapy in Acute Coronary Syndromes

The DUAL-ACS trial, a randomized multicenter study, was designed to evaluate whether a strategy of P2Y12 inhibitor...

Dr. Juan Manuel Pérez - 3 September, 2025

Acute coronary syndromes

ESC 2025 | OPTION-STEMI: Timing of Complete Revascularization During the Initial Hospitalization in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease

In patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD), the optimal timing...

Dr. Juan Manuel Pérez - 3 September, 2025

Acute coronary syndromes

Abbreviated Dual Antiplatelet Therapy with Prasugrel: 4D-ACS

The optimal duration of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) remains subject to controversy....

Dr. Omar Tupayachi - 3 August, 2025

Acute coronary syndromes

Use of Plaque Modifying Devices in Calcified Left Main Lesions

Treating severely calcified left main coronary artery (LMCA) lesions is one of the greatest challenges in interventional...

Dr. Omar Tupayachi - 25 July, 2025

Acute coronary syndromes

Early Discharge After STEMI: Clinical Benefit and Cost-Effectiveness?

Improvements in reperfusion strategies for ST-segment elevation myocardial infarction (STEMI) have transformed the prognosis for this condition....

Dr. Omar Tupayachi - 26 June, 2025

Acute coronary syndromes

PROSPECT II Substudy: Relationship Between Different Levels of hs-CRP and Vulnerable Plaque Characteristics in Patients with NSTEMI

Inflammation plays a key role in the onset and progression of atherosclerosis and has been linked to...

Dr. Andrés Rodríguez - 11 June, 2025

Acute coronary syndromes

ESC 2025 | BETAMI-DANBLOCK: Randomized Discontinuation of Beta-Blockers after MI

ESC 2025 | What Should We Do With Beta-Blockers Post-MI in Patients With Preserved LVEF?

ESC 2025 | DUAL-ACS: Duration of Dual Antiplatelet Therapy in Acute Coronary Syndromes

ESC 2025 | OPTION-STEMI: Timing of Complete Revascularization During the Initial Hospitalization in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease

Abbreviated Dual Antiplatelet Therapy with Prasugrel: 4D-ACS

Use of Plaque Modifying Devices in Calcified Left Main Lesions

Early Discharge After STEMI: Clinical Benefit and Cost-Effectiveness?

PROSPECT II Substudy: Relationship Between Different Levels of hs-CRP and Vulnerable Plaque Characteristics in Patients with NSTEMI

Últimas Noticias

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Is it really necessary to monitor all patients after TAVR?

Is it really necessary to monitor all patients after TAVR?

Noticias Institucionales

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

Accesos